Many patients with CML ultimately develop resistance to imatinib mesylate (IM) or second-generation kinase inhibitors (e.g., dasatinib). Furthermore, patients with Bcr/Abl + ALL respond less effectively to these agents. Such patients have few treatment options, justifying the search for more effective therapeutic strategies.
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Statement of translation relevance
Many patients with CML ultimately develop resistance to imatinib mesylate (IM) or second-generation kinase inhibitors (e.g., dasatinib). Furthermore, patients with Bcr/Abl + ALL respond less effectively to these agents. Such patients have few treatment options, justifying the search for more effective therapeutic strategies.
The Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 has been evaluated in 
Introduction
Chronic myelogenous leukemia (CML) is characterized by a reciprocal translation t(9;22)(q34;q11.2) resulting in the Philadelphia chromosome (Ph), which produces a constitutively active tyrosine kinase, Bcr/Abl [1] . Philadelphia chromosomepositive ALL occurs in approximately 20-30% of patients with ALL and carries a relatively poor prognosis [2] . The treatment of CML, and to a lesser extent Ph + ALL, has been revolutionized by the introduction of the Bcr/Abl kinase inhibitor imatinib mesylate; and subsequently, second-generation inhibitors such as nilotinib and the dual Src-Bcr/Abl inhibitors dasatinib and bosutinib [3, 4] . Unfortunately, resistance to imatinib or other kinase inhibitors generally develops, frequently reflecting the emergence of point mutations within various regions of the Bcr/Abl kinase although other mechanisms (e.g. increased Bcr/Abl expression, pharmacokinetic factors) may also be involved [5] . Mutations within the "gatekeeper", or contact region (e.g., T315I) are particularly intractable and confer resistance to most Bcr/Abl kinase inhibitors, including imatinib, nilotinib, dasatinib, and bosutinib [6] . Consequently, novel and more effective therapeutic strategies are urgently needed in this setting.
Progress in this area was stimulated by the observation that certain aurora kinase inhibitors (e.g., XL228, VX-680/MK0457, and PHA-379358) targeted both wild-type and mutant Bcr/Abl [4] . Aurora kinases represent a family of serine-threonine kinases intimately involved in cell cycle regulation, particularly mitotic progression. Aurora A kinase is associated with centrosome maturation and separation, required for spindle assembly; whereas Aurora B kinase is a chromosome passenger protein required for spindle checkpoint activation and cytokinesis [7, 8] . Recently, an orally active multikinase inhibitor (KW-2449) has been developed which inhibits T315I Bcr/Abl in vitro and in vivo, as well as multiple other kinases, including aurora kinase, FLT3, and FGFR-1 [9] . Notably, KW-2449 displays minimal cardiotoxicity, a toxicity which halted the development of VX-680/MK-0457. Importantly, KW-2449, like VX-680, has shown activity in cells obtained from imatinib (IM)-resistant patients bearing the T315I mutation [9] . Of late, the clinical development of KW-2449 has focused primarily on patients with FLT3-mutated AML [10] .
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HDAC inhibitors (HDACIs) represent a class of agents that block histone acetylation, induce a more open chromatin configuration, and activate genes that promote cell differentiation or death [11] . HDACIs (e.g., vorinostat and romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma (CTCL) [12] .
These agents kill leukemia cells through diverse mechanisms, including induction of oxidative injury, up-regulation of death receptors, and acetylation of non-histone proteins, among others [13] . We and other groups have shown that HDACIs promote the lethality of IM and other kinase inhibitors in Bcr/Abl + leukemias [14, 15] .
Recently, our group and others reported that the pan-HDACI vorinostat synergistically potentiated the activity of VX-680 in Bcr/Abl + leukemia cells, and was particularly effective against cells bearing various TKI resistance-conferring mutations (e.g., T315I) [16] [17] [18] . Unfortunately, VX-680-associated cardiotoxicity (QTc prolongation) rendered it unavailable for clinical use. However, the dual Bcr/Abl and aurora kinase inhibitor KW-2449, which has undergone clinical evaluation in Bcr/Abl + and Bcr/Abl -leukemias, represents a plausible alternative. The purpose of this study was to assess the effects of HDACIs (e.g., vorinosat, SBHA, SNDX-275) on responses to the dual Bcr/Abl-aurora kinase inhibitor KW-2449 in various Bcr/Abl+ lymphoid and myeloid leukemia cells, with a particular emphasis on those bearing mutations conferring resistance to imatinib mesylate (i.e. T315I and E255K).
Materials and Methods
Cell lines
The BV173/E255K cell line was generated from parental BV173 by increasing concentration of imatinib. Ba/F3 cells expressing wild-type and mutant forms of porphyrin (Mn-TBAP) was purchased from Calbiochem. Z-VAD-fmk was purchased from MP Biomedicals (Irvine, CA). Suberic bishydroxamate (SBHA) and apicidin were purchased from Biomol International.
Assessment of apoptosis
The extent of apoptosis was evaluated by either annexin V-fluorescein isothiocyanate (FITC) staining (BD Pharmigen) or 7-aminoactinomycin D (7-AAD, Sigma-Aldrich) by flow cytometry as described previously [19, 20] . Western blot analysis was performed as previously described [16] . The following were used as primary antibodies: cleaved caspase-3, cleaved PARP, p-STAT5 (Y694), p-CRKL (Y207), p-Aurora B from Cell Signaling Technology, Beverly, MA);
Measurement of ROS production
antiphosphotyrosine (4G10), p-Histone H3, γ-H2A.X (Upstate, Lake Placid, NY); Abl,
Cytochrome-c and apoptosis-inducing factor (AIF) (Santa Cruz, CA); and actin and tubulin (Sigma-Aldrich). Blots were stripped and reprobed with actin or tubulin antibodies to ensure equal loading and transfer of proteins. Analysis of cytosolic released proteins was performed as previously described [21] .
Sequencing of the BCR/ABL ATP binding site
Total RNA was extracted using the RNeasy mini kit (QIAGEN). One microgram of RNA was subjected to RT-PCR (AccuScript The significance of differences between experimental conditions was determined using [23] , the effects of HDACIs on KW2449-induced DNA damage was examined. Expression of γH2A.X, a marker of double-stranded DNA breaks, was increased in K562, LAMA, BV173/E255K, and Adult/T315I cells exposed to KW24449/vorinostat or KW2449/SNDX compared to the effects of single drug exposure ( Figure 4A ). Moreover, induction of γH2A.X in cells exposed to KW2449/HDACi was detected as early as 6 hr after drug exposure and was extensive at 24 hr, as determined by confocal microscopy (data not shown). Notably, in contrast to effects on caspase-3 cleavage, which was completely blocked, the pan-caspase inhibitor fmk-ZVAD (20 µM) had little or no effect on KW2449/vorinostat-mediated inactivation of Bcr/Abl or γH2A.X formation ( Figure 4B Reactive oxygen species (ROS) have been implicated in HDACI-mediated induced cell death [24, 25] . To explore the possible role of ROS generation in the lethality of HDACI/KW2449 regimens, ROS were monitored by flow cytometry using HE, a dye that is relatively specific for nilotinib, numerous challenges persist [3] . First, the accelerated and blast crisis phases of CML are considerably less responsive to these agents than chronic phase disease.
Furthermore, despite initial responses, patients with CML as well as Ph + ALL develop resistance to IM and second-generation agents (niloditib, dasatinib) [5, 26] . This frequently involves mutations, often in the gatekeeper region (e.g. T315I, F317L), which disrupt contact between IM (or second-generation Bcr/Abl kinase inhibitors) and Bcr/Abl, conferring resistance on affected cells [4] . The fortuitous finding that certain aurora kinase inhibitors inhibited Bcr/Abl + leukemia cells bearing such mutations provided a new therapeutic strategy in the setting of IM-resistant disease [27] . Although the multi-kinase inhibitor KW2449, which also inhibits Bcr/Abl and aurora kinases, has primarily been developed as a FLT3 inhibitor in AML [10] , preclinical studies demonstrate that it effectively kills Bcr/Abl + leukemias, including Ph + ALL, bearing gatekeeper mutations [9] . The finding that HDACIs promoted the activity of first and second generation Bcr/Abl inhibitors [14, 15, 28, 29] prompted efforts to determine whether they could also potentiate the lethality of third generation agents. Indeed, the pan-HDACI vorinostat increased VX-680 activity against IM-sensitive and IM-resistant Bcr/Abl+ myeloid and lymphoid leukemia cells in preclinical studies [16] [17] [18] . However, To the best of our knowledge, the present findings are the first to demonstrate that HDACIs promote oxidative injury induced by KW2449, and that this event plays a significant functional role in enhanced lethality. Specifically, both vorinostat and SNDX-275 potentiated KW2449-induced ROS formation in both IM-sensitive and IMresistant mutant cells, and the lethality of HDACI/KW2449 regimens, was significantly attenuated by the antioxidant TBAP. Among their diverse actions, HDACIs, including both vorinostat and SNDX-275, have been shown to trigger transformed cell death through ROS generation [24, 25] . The preferential induction of oxidative injury has also been implicated in HDACI selectivity toward transformed cells [33] . On the other hand, evidence that Bcr/Abl kinase inhibitors exert their lethal effects toward Bcr/Abl + leukemias via oxidative injury is largely lacking. Interestingly, it has been reported that Bcr/Abl kinase inhibitors such as IM trigger genomic instability through ROS generation, leading to the development of resistance-conferring mutations in Bcr/Abl [34] . One possible explanation for these apparently paradoxical phenomena is that in cells exposed to kinase inhibitors alone, ROS generation may be sub-lethal but mutagenic; whereas in the presence of HDACIs, the levels of ROS exceed the threshold for cell death induction. The basis for the observed increases in ROS generation is unclear, but may be related to events stemming from Bcr/Abl kinase inhibition i.e., DNA damage induction, diminished DNA repair, and impaired DNA damage checkpoint regulation.
The finding that HDACIs potentiated DNA damage induced by KW2449 (or other Bcr/Abl kinase inhibitors) reflected by increased expression of λH2A.X, a marker for double-strand DNA breaks, has also not been previously described. Because such breaks can occur in cells undergoing apoptosis, it is possible that these phenomena represent secondary events. However, the finding that pan-caspase inhibitors, which blocked apoptosis, failed to diminish λH2A.X formation, argues against this possibility. 
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relevant that Bcr/Abl kinase inhibitors such as IM have been shown to compromise genomic stability and DNA repair by inhibiting c-Abl [35] , and to interfere with nucleotide excision repair in Bcr/Abl-expressing cells, including K562 and BV173 [23] .
Analogously, HDACIs can disrupt DNA repair through multiple mechanisms i.e., acetylation of Ku70 [36] and down-regulation of DNA repair proteins such as RAD51 [37] . Interestingly, such phenomena have been reported to occur preferentially in transformed cells [38] . It is conceivable that these events cooperate to promote DNA damage in the face of increased ROS production. The possibility that disruption of DNA damage checkpoints contributes to these events also cannot be excluded.
Histone H3 phosphorylation is a hallmark of mitosis which is mediated by Aurora kinase B. In previous studies involving VX-680 and vorinostat, a clear reduction of phospho-histone H3 was observed with combined treatment [16] . Although in the present study, KW2449 alone diminished expression of phospho-histone H3, consistent with previous reports [39] , potentiation of this effect by HDACIs was not observed.
This may reflect the fact that VX680 primarily inhibits Aurora kinase B and A compared to Abl, with IC 50 values of 0.18, 0.6 and 20 nM respectively; whereas KW2449 exhibits a stronger affinity for Abl than Aurora kinases (A and B), with IC 50 values of 14 and 48nM respectively [40] . However, the possibility that aurora kinaserelated effects of KW2449 on DNA damage checkpoints or DNA repair processes contribute to interactions with HDACIs cannot be excluded. 
It is noteworthy that
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including those expressing highly IM-resistant variants, including phosphorylation loop (E255K) and gatekeeper (T315I). The basis for lethality is likely to be multi-factorial, including induction of oxidative injury and DNA damage, interruption of Bcr/Abl signaling pathways (e.g., CRKL, STAT-5), and possibly interference with DNA damage checkpoints and/or DNA repair events. Importantly, HDACI/KW-2449 regimens significantly increased the survival of mice bearing IM-resistant cells expressing the E255K mutation. One remaining question is whether this strategy would be active against quiescent CML stem cells, which are characteristically resistant to kinase inhibitors [41] . In this context, HDACIs have recently been shown to potentiate the activity of IM against such cells [28] . It would therefore be interesting to learn whether they might exert similar effects in combination with third-generation Bcr/Abl kinase inhibitors such as KW-2449. Accordingly, studies to test this possibility are underway.
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